0001392449false--12-31falseQ220220.001100000000000.001250000000200064022000640220006402000000013924492022-01-012022-06-300001392449us-gaap:SubsequentEventMember2022-07-010001392449us-gaap:RetainedEarningsMember2022-04-012022-06-300001392449us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001392449us-gaap:CommonStockMember2022-04-012022-06-300001392449us-gaap:PreferredStockMember2022-04-012022-06-3000013924492022-03-310001392449us-gaap:RetainedEarningsMember2022-03-310001392449us-gaap:AdditionalPaidInCapitalMember2022-03-310001392449us-gaap:CommonStockMember2022-03-310001392449us-gaap:PreferredStockMember2022-03-310001392449us-gaap:RetainedEarningsMember2022-06-300001392449us-gaap:AdditionalPaidInCapitalMember2022-06-300001392449us-gaap:CommonStockMember2022-06-300001392449us-gaap:PreferredStockMember2022-06-300001392449us-gaap:RetainedEarningsMember2022-01-012022-06-300001392449us-gaap:AdditionalPaidInCapitalMember2022-01-012022-06-300001392449us-gaap:CommonStockMember2022-01-012022-06-300001392449us-gaap:PreferredStockMember2022-01-012022-06-300001392449us-gaap:RetainedEarningsMember2021-12-310001392449us-gaap:AdditionalPaidInCapitalMember2021-12-310001392449us-gaap:CommonStockMember2021-12-310001392449us-gaap:PreferredStockMember2021-12-310001392449us-gaap:RetainedEarningsMember2021-04-012021-06-300001392449us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001392449us-gaap:CommonStockMember2021-04-012021-06-300001392449us-gaap:PreferredStockMember2021-04-012021-06-3000013924492021-03-310001392449us-gaap:RetainedEarningsMember2021-03-310001392449us-gaap:AdditionalPaidInCapitalMember2021-03-310001392449us-gaap:CommonStockMember2021-03-310001392449us-gaap:PreferredStockMember2021-03-3100013924492021-06-300001392449us-gaap:RetainedEarningsMember2021-06-300001392449us-gaap:AdditionalPaidInCapitalMember2021-06-300001392449us-gaap:CommonStockMember2021-06-300001392449us-gaap:PreferredStockMember2021-06-300001392449us-gaap:RetainedEarningsMember2021-01-012021-06-300001392449us-gaap:AdditionalPaidInCapitalMember2021-01-012021-06-300001392449us-gaap:CommonStockMember2021-01-012021-06-300001392449us-gaap:PreferredStockMember2021-01-012021-06-3000013924492020-12-310001392449us-gaap:RetainedEarningsMember2020-12-310001392449us-gaap:AdditionalPaidInCapitalMember2020-12-310001392449us-gaap:CommonStockMember2020-12-310001392449us-gaap:PreferredStockMember2020-12-3100013924492021-01-012021-06-3000013924492021-04-012021-06-3000013924492022-04-012022-06-3000013924492021-12-3100013924492022-06-3000013924492022-08-09iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_______________________
FORM 10-Q
_______________________
(Mark One)
☒
|
Quarterly Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
|
For the quarterly period ended June 30, 2022
or
☐
|
Transition Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
|
For the transition period from___________ to ____________
Commission file number 000-52622
GREEN PLANET BIOENGINEERING
CO., LTD.
|
(Exact Name of Registrant as Specified in its charter)
|
Delaware
|
|
37-1532842
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
20807 Biscayne Blvd., Suite 203,
Aventura, Florida
|
|
33180
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(786) 279-2900
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any, every
Interactive Data File required to be submitted and posted pursuant
to Rule 405 of Regulation S-T (§232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). Yes ☐ No ☐
Indicate by checkmark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of “large accelerated
filer,” “accelerated filer” and “smaller reporting company” in Rule
12b-2 of the Exchange Act. (Check one):
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
Non-accelerated filer
|
☐
|
Smaller reporting company
|
☒
|
(Do not check if a smaller company)
|
|
|
|
If
an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act)
Yes ☒ No ☐
The number of shares of common stock outstanding as of August 9,
2022 was 20,006,402.
TABLE OF
CONTENTS
INTERIM FINANCIAL STATEMENTS
The unaudited interim financial statements have been prepared in
accordance with generally accepted accounting principles in the
United States for interim financial information and with the
instructions under Regulation S-X of the Securities and Exchange
Commission (“SEC”) Form 10-Q. Accordingly, they do not include all
the information and footnotes required by generally accepted
accounting principles for complete financial statements. Therefore,
these financial statements should be read in conjunction with the
Company’s audited financial statements and notes thereto for the
year ended December 31, 2021.
The financial statements included herein are unaudited; however,
they contain all normal recurring accruals and adjustments that, in
the opinion of management, are necessary to present fairly the
Company’s financial position as of the period reporting date, and
the results of its operations and cash flows for the fiscal period
end. The results of operations for the fiscal period end are not
necessarily indicative of the results to be expected for future
quarters or the full fiscal year.
FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934. These statements involve risks and
uncertainties, including, among other things, statements regarding
our business strategy, future revenues and anticipated costs and
expenses. Such forward-looking statements include, among others,
those statements including the words “expects,” “anticipates,”
“intends,” “believes,” “may,” “will,” “should,” “could,” “plans,”
“estimates,” and similar language or negative of such terms. Our
actual results may differ significantly from those projected in the
forward-looking statements. Factors that might cause or contribute
to such differences include, but are not limited to, those
discussed in Item 2 “Management’s Discussion and Analysis of
Financial Condition and Results of Operations.” You are cautioned
not to place undue reliance on the forward-looking statements,
which speak only as of the date of this report. Although we believe
that the expectations reflected in the forward-looking statements
are reasonable, we do not know whether we can achieve positive
future results, levels of activity, performance, or goals. Actual
events or results may differ materially. We undertake no obligation
to publicly release any revisions to the forward-looking statements
or reflect events or circumstances taking place after the date of
this document.
PART I FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
Green Planet Bioengineering Co., Ltd.
Condensed Balance Sheets
|
|
June 30, |
|
|
December 31,
|
|
|
|
2022 |
|
|
2021
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
|
|
Cash
|
|
$ |
- |
|
|
$ |
- |
|
|
|
|
|
|
|
|
|
TOTAL CURRENT ASSETS
|
|
$ |
- |
|
|
$ |
- |
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ DEFICIT
|
|
|
|
|
|
|
|
|
LIABILITIES
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
|
|
|
Amount due to a related party
|
|
$ |
368,494 |
|
|
$ |
349,387 |
|
|
|
|
|
|
|
|
|
TOTAL CURRENT LIABILITIES
|
|
|
368,494 |
|
|
|
349,387 |
|
|
|
|
|
|
|
|
|
|
Commitments and Contingencies
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
STOCKHOLDERS’ DEFICIT
|
|
|
|
|
|
|
|
|
Preferred stock: par value of $0.001 per share
|
|
|
|
|
|
|
|
|
Authorized: 10,000,000 shares at June 30, 2022 and December 31,
2021
|
|
|
|
|
|
|
|
|
Issued and outstanding: 0 shares at June 30, 2022 and December 31,
2021
|
|
|
- |
|
|
|
- |
|
Common stock: par value of $0.001 per share
|
|
|
|
|
|
|
|
|
Authorized: 250,000,000 shares at June 30, 2022 and December 31,
2021
|
|
|
|
|
|
|
|
|
Issued and outstanding: 20,006,402 shares at June 30, 2022 and
December 31, 2021
|
|
|
20,006 |
|
|
|
20,006 |
|
Additional paid-in-capital
|
|
|
609,614 |
|
|
|
609,614 |
|
Accumulated deficit
|
|
|
(998,114 |
) |
|
|
(979,007 |
) |
|
|
|
|
|
|
|
|
TOTAL STOCKOLDERS’ DEFICIT
|
|
|
(368,494 |
) |
|
|
(349,387 |
) |
|
|
|
|
|
|
|
|
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT
|
|
$ |
- |
|
|
$ |
- |
|
See Notes to the Unaudited Condensed Financial Statements
Green Planet Bioengineering Co., Ltd.
Condensed Statements of
Operations
(Unaudited)
|
|
Three months ended June 30,
|
|
|
Six months ended June 30,
|
|
|
|
2022
|
|
|
2021
|
|
|
2022
|
|
|
2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Administrative expenses
|
|
$ |
(5,449 |
) |
|
$ |
(3,958 |
) |
|
$ |
(19,107 |
) |
|
$ |
(12,930 |
) |
Loss before income taxes
|
|
|
(5,449 |
) |
|
|
(3,958 |
) |
|
|
(19,107 |
) |
|
|
(12,930 |
) |
Provision for income taxes
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$ |
(5,449 |
) |
|
$ |
(3,958 |
) |
|
$ |
(19,107 |
) |
|
$ |
(12,930 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss per share -Basic and diluted
|
|
$ |
( * )
|
|
|
$ |
( * )
|
|
|
$ |
( * )
|
|
|
$ |
( * )
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares outstanding -Basic and
diluted
|
|
|
20,006,402 |
|
|
|
20,006,402 |
|
|
|
20,006,402 |
|
|
|
20,006,402 |
|
*
|
Less than $.01, per share
|
See Notes to the Unaudited Condensed Financial Statements
Green Planet Bioengineering Co., Ltd
Condensed Statements of Changes in Stockholders’
Deficit
For the Three and Six Months Ended June 30, 2022 and
2021
(Unaudited)
|
|
Preferred Stock
|
|
|
Common Stock
|
|
|
|
|
|
|
|
|
|
|
|
|
Number
of shares
|
|
|
Amount
|
|
|
Number
of shares
|
|
|
Amount
|
|
|
Additional
paid-in
capital
|
|
|
Accumulated
deficit
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, December 31, 2020
|
|
|
- |
|
|
$ |
- |
|
|
|
20,006,402 |
|
|
$ |
20,006 |
|
|
$ |
609,614 |
|
|
$ |
(946,078 |
) |
|
$ |
(316,458 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the six months
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(12,930 |
) |
|
|
(12,930 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance June 30, 2021 (Unaudited)
|
|
|
- |
|
|
$ |
- |
|
|
|
20,006,402 |
|
|
$ |
20,006 |
|
|
$ |
609,614 |
|
|
$ |
(959,008 |
) |
|
$ |
(329,388 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, March 31, 2021 (Unaudited)
|
|
|
- |
|
|
$ |
- |
|
|
|
20,006,402 |
|
|
$ |
20,006 |
|
|
$ |
609,614 |
|
|
$ |
(955,050 |
) |
|
$ |
(325,430 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the three months
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(3,958 |
) |
|
|
(3,958 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance June 30, 2021 (Unaudited)
|
|
|
- |
|
|
$ |
- |
|
|
|
20,006,402 |
|
|
$ |
20,006 |
|
|
$ |
609,614 |
|
|
$ |
(959,008 |
) |
|
$ |
(329,388 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, December 31, 2021
|
|
|
- |
|
|
$ |
- |
|
|
|
20,006,402 |
|
|
$ |
20,006 |
|
|
$ |
609,614 |
|
|
$ |
(979,007 |
) |
|
$ |
(349,387 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the six months
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(19,107 |
) |
|
|
(19,107 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, June 30, 2022 (Unaudited)
|
|
|
- |
|
|
$ |
- |
|
|
|
20,006,402 |
|
|
$ |
20,006 |
|
|
$ |
609,614 |
|
|
$ |
(998,114 |
) |
|
$ |
(368,494 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, March 31, 2022 (Unaudited)
|
|
|
- |
|
|
$ |
- |
|
|
|
20,006,402 |
|
|
$ |
20,006 |
|
|
$ |
609,614 |
|
|
$ |
(992,665 |
) |
|
$ |
(363,045 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the three months
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(5,449 |
) |
|
|
(5,449 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance June 30, 2022 (Unaudited)
|
|
|
- |
|
|
$ |
- |
|
|
|
20,006,402 |
|
|
$ |
20,006 |
|
|
$ |
609,614 |
|
|
$ |
(998,114 |
) |
|
$ |
(368,494 |
) |
See Notes to the Unaudited Condensed Financial Statements
Green Planet Bioengineering Co., Ltd.
Condensed Statements of Cash
Flows
(Unaudited)
|
|
Six months ended June 30,
|
|
|
|
2022
|
|
|
2021
|
|
|
|
|
|
|
|
|
Cash flows from operating activities
|
|
|
|
|
|
|
|
|
Net loss
|
|
$ |
(19,107 |
) |
|
$ |
(12,930 |
) |
|
|
|
|
|
|
|
|
|
Net cash flows used by operating activities
|
|
|
(19,107 |
) |
|
|
(12,930 |
) |
|
|
|
|
|
|
|
|
|
Cash flows from financing activities
|
|
|
|
|
|
|
|
|
Amount due to a related company
|
|
|
19,107 |
|
|
|
12,930 |
|
|
|
|
|
|
|
|
|
|
Net cash flows provided by financing
activities
|
|
|
19,107 |
|
|
|
12,930 |
|
|
|
|
|
|
|
|
|
|
Net decrease in cash and cash equivalents
|
|
|
- |
|
|
|
- |
|
Cash – beginning of period
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
Cash – end of period
|
|
$ |
- |
|
|
$ |
- |
|
|
|
|
|
|
|
|
|
|
Supplemental disclosures for cash flow information:
|
|
|
|
|
|
|
|
|
Cash paid for interest
|
|
$ |
- |
|
|
$ |
- |
|
|
|
|
|
|
|
|
|
|
Cash paid for income taxes
|
|
$ |
- |
|
|
$ |
- |
|
See Notes to
the Unaudited Condensed Financial Statements
Green Planet Bioengineering Co., Ltd
Notes to the Condensed Financial
Statements
(Unaudited)
1. General Information
Mondo Acquisition II, Inc. was incorporated in the State of
Delaware on October 30, 2006 and changed the name to Green Planet
Bioengineering Co., Ltd. (“Company”) on October 2, 2008. In October
2008, the Company acquired Elevated Throne Overseas Ltd,
incorporated in British Virgin Islands, and its subsidiaries which
was subsequently divested to One Bio, Corp (“ONE”) on April 14,
2010.
In March 2012, the Company became a subsidiary of Global Fund
Holdings Corp. (“Global Funds”) an Ontario, Canada Corporation.
The Company operates as a public reorganized shell corporation with
the purpose to acquire or merge with an existing business
operation. The Company’s activities are subject to significant
risks and uncertainties, as their ability to implement and execute
future business plans and generate sufficient business revenue is
directly influenced by their ability to secure adequate financing
or find profitable business opportunities.
2. Summary of significant accounting policies
Basis of Presentation
The accompanying unaudited condensed financial statements have been
prepared in accordance with United States generally accepted
accounting principles for interim financial information and with
the instructions to Form 10-Q of Regulation S-K. They may not
include all information and footnotes required by United States
generally accepted accounting principles for complete financial
statements. However, except as disclosed herein, there have been no
material changes in the information disclosed in the notes to the
financial statements for the year ended December 31, 2021 included
in the Company’s Annual Report on Form 10-K filed with the United
States Securities and Exchange Commission. The unaudited condensed
financial statements should be read in conjunction with those
financial statements included in the Form 10-K. In the opinion of
management, all adjustments considered necessary for a fair
presentation, consisting solely of normal and recurring adjustments
have been made. Operating results for the three and six months
ended June 30, 2022 are not necessarily indicative of the results
that may be expected for the fiscal year ending December 31,
2022.
Use of Estimates
The preparation of financial statements in accordance with U.S.
GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and the
disclosure of contingent assets and liabilities as of the date of
the financial statements and the reported amounts of revenue and
expenses for the years reported. Actual results could differ from
those estimates. Significant items that require estimates were
accruals of liabilities.
Cash and cash equivalents
Cash and cash equivalents include all cash, deposits in banks and
other highly liquid investments with initial maturities of three
months or less to be cash equivalents. Balances of cash and cash
equivalents in financial institutions may at times exceed the
government-insured limits.
Loss per share
Earnings per share is reported in accordance with FASB ASC Topic
260 “Earnings per Share” which requires dual presentation
of basic earnings per share (“EPS”) and diluted EPS on the face of
all statements of earnings, for all entities with complex capital
structures. Diluted EPS reflects the potential dilution that could
occur from common shares issuable through the exercise or
conversion of stock options, restricted stock awards, warrants and
convertible securities. In certain circumstances, the conversion of
these options, warrants and convertible securities are excluded
from diluted EPS if the effect of such inclusion would be
anti-dilutive. Fully diluted EPS is not provided, when the effect
is anti-dilutive. When the effect of dilution on loss per share is
anti-dilutive, diluted loss per share equals the loss per share. As
of June 30, 2022 and 2021, the Company does not have any common
share equivalents outstanding.
2. Summary of Significant Accounting Policies –
continued
Fair Value Measurements
FASB ASC Topic 820, “Fair Value Measurements and
Disclosures” defines fair value, establishes a framework for
measuring fair value in accordance with U.S. GAAP, and expands
disclosures about fair value measurements. Investment measured and
reported at fair value are classified and disclosed in one of the
following hierarchy:
Level 1 - Quoted prices are available in active markets for
identical investments as of the period reporting date.
Level 2 - Pricing inputs are other than quoted prices in active
markets, which are either directly or indirectly observable as of
the reporting date, and fair value is determined through the use of
models or other valuation methodologies.
Level 3 - Pricing inputs are unobservable for the investment and
included situations where there is little, if any, market activity
for the investment. The inputs into the determination of fair value
require significant management judgment or estimation.
Recent Changes in Accounting Standards
Management does not believe that any other recently issued, but not
yet effective accounting pronouncements, if adopted, would have a
material effect on the accompanying unaudited condensed financial
statements.
3. Going Concern
The unaudited condensed financial statements have been prepared
assuming that the Company will continue as a going concern. The
Company is currently a public reorganized shell corporation and has
no current business activity. The Company’s ability to continue as
a going concern is dependent on continued support from a related
party of the majority stockholder. This gives rise to substantial
doubt about the Company’s ability to continue as a going
concern.
4. Amount Due to a Related Company
The Company relies on a related party of the majority stockholder
to advance funds to finance its operating expenses. The Company’s
Chief Executive Officer, Chief Financial Officer and Director of
the Company is also a director of the related party. The amounts
advanced of $368,494 are interest-free, unsecured and are repayable
upon demand.
5. Preferred stock / Common stock
Series A Preferred stock
The Company is authorized under its Articles of Incorporation to
issue 10,000,000 shares of Series A preferred stock with a par
value of $0.001 per share. Each share of the Company’s preferred
stock provides the holder with the right to vote 1,000 votes on all
matters submitted to a vote of the stockholders of the Company and
is convertible into 1,000 shares of the Company’s common stock. The
preferred stock is non-participating and carries no dividend.
The company does not have any issued shares of the preferred stock
as of June 30, 2022 and December 31, 2021.
Common stock
The Company is authorized to issue 250,000,000 shares of common
stock with a par value of $0.001 per share. During the six months
ended June 30, 2022, the Company did not issue any shares of common
stock or warrants.
6. Subsequent Events
The related party advanced the Company $35 from July 1, 2022
through the date of filing.
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
General Overview
The Company operates as a public reorganized corporation with the
business purpose to acquire or merge with an existing business
operation.
Results of Operations and Financial Condition for the three and
six months ended June 30, 2022, as compared to the three and six
months ended June 30, 2021.
The Company had no active business operations for the periods ended
June 30, 2022 and June 30, 2021. Expenses consist of accounting and
filing fees.
Liquidity and capital resources
The Company had no active business operations for the three and six
months ended June 30, 2022. Accordingly, all the Company’s cash
flow needs were provided by a related party of Global Funds, the
majority stockholder to pay expenses necessary as of public
company.
Going forward, the Company will continue to source adequate funding
from future investors to execute business opportunities when they
arise in the future. However, such funding and business
opportunities will rely entirely on the prevailing circumstances
when the funding or profitable business opportunities are
identified. If such opportunities are not identified in the near
term, the Company will experience delay in effecting its business
plans.
The financial statements have been prepared assuming that the
Company will continue as going concern. The Company is currently a
public reorganized shell corporation and has no current business
activity. The Company’s ability to continue as a going concern is
dependent on continued support from a related party of Global
Funds, a majority stockholder. This gives rise to substantial doubt
about the Company’s ability to continue as a going concern.
Risk factors
The Company’s critical accounting policies are still being applied
despite the fact that Company has no ongoing business
operations.
Significant Estimates
We prepare our financial statements in conformity with generally
accepted accounting principles in the United States of America. As
such, we are required to make estimates, judgments and assumptions
that we believe are reasonable based upon historical experience,
current trends and other factors. These estimates, judgments and
assumptions affect the reported amounts of assets and liabilities
at the date of the financial statements and the reported amounts of
revenue and expenses during the periods presented. Actual results
could be different than those estimates.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have or are
reasonably likely to have a current or future effect on our
financial condition, changes in financial condition, revenues or
expenses, results of operations, liquidity, capital expenditures or
capital resources that is material to investors.
Market Risks
There has been no material change in market risks since our last
Annual Report on Form 10-K for the year ended December 31,
2021.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK
None.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and
Procedures
Our management, with the participation of our chief executive
officer and chief financial officer, evaluated the effectiveness of
our disclosure controls and procedures pursuant to Rule 13a-15
under the Securities Exchange Act of 1934, as amended (Exchange
Act), as of the end of the period covered by this Quarterly Report
on Form 10-Q.
Based on this evaluation, our chief executive officer and
chief financial officer concluded that, as of the fiscal period
end, our disclosure controls and procedures are designed at a
reasonable assurance level and are effective to provide reasonable
assurance that information we are required to disclose in reports
that we file or submit under the Exchange Act is recorded,
processed, summarized, and reported within the time periods
specified in the SEC’s rules and forms, and that such information
is accumulated and communicated to our management, including our
chief executive officer and chief financial officer, as
appropriate, to allow timely decisions regarding required
disclosure.
Changes in Internal Control over Financial
Reporting
There were no changes in our internal control over financial
reporting that occurred during the quarter ended June 30, 2022 that
have materially affected, or are reasonably likely to materially
affect, our internal control over financial reporting.
Limitations on Effectiveness of Controls and
Procedures
In designing and evaluating the disclosure controls and procedures,
management recognizes that any controls and procedures, no matter
how well designed and operated, can provide only reasonable
assurance of achieving the desired control objectives. In addition,
the design of disclosure controls and procedures must reflect the
fact that there are resource constraints and that management is
required to apply its judgment in evaluating the benefits of
possible controls and procedures relative to their costs.
PART II OTHER
INFORMATION
ITEM 1. LEGAL PROCEEDINGS
None
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES
AND USE OF PROCEEDS
None
ITEM 3. DEFAULTS UPON SENIOR
SECURITIES
None
ITEM 4. RESERVED
ITEM 5. OTHER INFORMATION
None
ITEM 6.
EXHIBITS
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned;
thereunto duly authorized this 9th day of August, 2022.
|
GREEN PLANET BIOENGINEERING CO., LTD.
|
|
|
|
|
|
Date: August 9,
2022 |
By: |
/s/ Jordan
Weingarten |
|
|
|
Jordan Weingarten |
|
|
|
President (Principal Executive Officer
and Principal Financial and Accounting
Officer) and Director
|
|
|
|
|
|
Green Planet Bioengineer... (PK) (USOTC:GPLB)
Historical Stock Chart
From May 2023 to Jun 2023
Green Planet Bioengineer... (PK) (USOTC:GPLB)
Historical Stock Chart
From Jun 2022 to Jun 2023